About Us
Corporate Overview
Imepro is a full support CRO with strengths in the pediatric and ophthalmology fields.
Established in 2011, we have offices in Tokyo and Osaka. By collaborating with stakeholders in drug development, Imepro contributes to the early approval of new drugs and medical devices.
Message
Representative message
We at Imepro were established with the aim of promoting drug development in the pediatric field and have supported numerous developments in this area. At the core of our mission is the desire to listen to social issues and to be an essential presence in the advancement of health and medicine.
At Imepro, like-minded colleagues who share this vision gather and work towards achieving high quality. Today, we have expanded our focus beyond the pediatric field to include ophthalmology as well.
As a full-support CRO, we provide comprehensive services and have embarked on the challenge of efficient drug development utilizing real-world data and technology.
Moving forward, we aim to collaborate with stakeholders to shape and create the future of drug development, striving to be a true partner as we navigate the coming new normal in pharmaceutical development.
Idea
Mission
We take the lead in fulfilling the truly needed roles in the advancement of medicine and healthcare, especially in the pediatric field
Value
We value teamwork and the spirit of challenge
Vision
Demonstrate the power of data and IT to become a trusted development partner
Approach to Work
Always envision success, think about what needs to be done now to achieve it, and take immediate action once you have an idea.
All problems can be solved through relationships between people. The technology will follow.
All members constantly discuss their thoughts with each other, ensuring that no one is left behind.
Company Profile
Company Name
Imepro Inc.
Tokyo Office
5F Sumitomo Shiba Daimon Building,
2-5-5 Shiba Daimon Minato-ku, 105-0012, Tokyo
TEL: +81-3-6661-6623
Osaka Office
4F EUNTO Honmachi Building,
4-4-10 Honmachi, Chuo-ku, Osaka City, 541-0053, Osaka
Board Member
Representative Director and President: Shinichi Keino
Director: Ryo Noguchi
Director: Kotaro Ujihara
Director: Yusuke Nakamura
Auditor: Yuta Fukami
Advisor
<Advisor>
Dr. Shun Nakayama,
Visiting Associate Professor, Tokyo Medical and Dental University
Dr. Takeshi Kimura
Toyonaka City Hospital, Part-time physician
Rinku General Medical Center, Part-time physician
Department of Pharmacoepidemiology, Department of Social Health Medicine,
Doctoral Program, Graduate School of Medicine, Kyoto University
Journal of the Japanese Pediatric Society, Statistical Reviewer
Director of Clinical Research, Organization for the Promotion of Information
Evaluation and Medical Education, General Incorporated Association
Dr. Masayu Hattori
Part-time physician, Tokyo Hikifune Hospital
Establishment
April 11, 2011
Capital
12 million yen
Shareholder Composition
Affiliated Organizations
Japan CRO Association
Kansai Pharmaceutical Association
Japan QA Study Group
Clinical Evaluation Study Group
History
QMS System
Achieving customer satisfaction through understanding and understanding requirements
Quality Policy
In order to effectively support clinical development overall with the most appropriate methods, we maintain high ethical standards, comply with regulations, and continually improve our quality management system.
PDCA
Access
Tokyo Office
5F Shibadaimon building, 2-5-5 Shiba Daimon, Minato-ku,
105-0012, Tokyo
-
Toei Oedo Line Toei Asakusa Line 'Daimon Station' Exit A3 2-minute walk
-
Yamanote Line, Keihin-Tohoku Line, Tokyo Monorail 'Hamamatsucho Station' Kanasugibashi Exit, 4 minutes on foot
-
Toei Mita Line 'Shiba Park Station' Exit A3, 5-minute walk
Osaka Office
4F IENTO Honmachi Building, 4-4-10 Honmachi, Chuo-ku, Osaka City, Osaka, 541-0053, Osaka
-
1 minute walk from Honmachi Station
-
10 minutes from Sakaisuji-Hommachi Station
-
12 minutes from Yodoyabashi Station
-
13 minutes from Shinsaibashi Station